aminolevulinic acid has been researched along with Mitochondrial Diseases in 4 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Mitochondrial Diseases: Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Aminolevulinic acid (5-ALA) is a crucial precursor of heme, which is essential for CII, complex III, complex IV (CIV) and cytochrome c activities." | 1.91 | 5-Aminolevulinic acid bypasses mitochondrial complex I deficiency and corrects physiological dysfunctions in Drosophila. ( Ando, K; Asada, A; Ishii, T; Ishizuka, M; Noguchi, M; Nozawa, N; Saito, T; Shinno, K; Takahashi, K, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nozawa, N | 2 |
| Noguchi, M | 1 |
| Shinno, K | 1 |
| Saito, T | 1 |
| Asada, A | 1 |
| Ishii, T | 2 |
| Takahashi, K | 2 |
| Ishizuka, M | 1 |
| Ando, K | 1 |
| Shimura, M | 1 |
| Ogawa-Tominaga, M | 1 |
| Fushimi, T | 1 |
| Tajika, M | 1 |
| Ichimoto, K | 1 |
| Matsunaga, A | 1 |
| Tsuruoka, T | 1 |
| Kishita, Y | 1 |
| Tanaka, T | 1 |
| Nakajima, M | 1 |
| Okazaki, Y | 1 |
| Ohtake, A | 1 |
| Murayama, K | 1 |
| Shroads, AL | 1 |
| Coats, BS | 1 |
| McDonough, CW | 1 |
| Langaee, T | 1 |
| Stacpoole, PW | 1 |
| Nakamura, Y | 1 |
| Haraguchi, A | 1 |
| Shigeno, R | 1 |
| Ito, A | 1 |
| Horie, I | 1 |
| Kawakami, A | 1 |
| Abiru, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:[NCT02616484] | Phase 3 | 34 participants (Actual) | Interventional | 2020-07-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for aminolevulinic acid and Mitochondrial Diseases
| Article | Year |
|---|---|
Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children.
Topics: Acetone; Adolescent; Adult; Aminolevulinic Acid; Child; Child, Preschool; Dichloroacetic Acid; Doubl | 2015 |
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
Topics: Adenosine Triphosphate; Adult; Aminolevulinic Acid; Blood Glucose; Citric Acid; Deafness; Diabetes M | 2021 |
2 other studies available for aminolevulinic acid and Mitochondrial Diseases
| Article | Year |
|---|---|
5-Aminolevulinic acid bypasses mitochondrial complex I deficiency and corrects physiological dysfunctions in Drosophila.
Topics: Adenosine Triphosphate; Aminolevulinic Acid; Animals; Drosophila; Heme Oxygenase-1; Lactates; Mitoch | 2023 |
Effects of 5-aminolevulinic acid and sodium ferrous citrate on fibroblasts from individuals with mitochondrial diseases.
Topics: Adenosine Triphosphate; Aminolevulinic Acid; Biosynthetic Pathways; Case-Control Studies; Citric Aci | 2019 |